SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc. (OTCQB:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present pre-clinical and clinical data for its TLR9 immune system agonist, AST-008, in two poster sessions at the AACR Annual Meeting 2019 in Atlanta, Georgia from March 29 – April 03, 2019.
“On behalf of the Exicure team, we are pleased to announce these two posters which underscore the importance of Exicure’s SNA technology for immune therapy against cancer,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “The first poster shows the high potency activation of effector immune cells by our immune system agonist AST-008 after administration of AST-008 to healthy volunteers in a Phase 1 clinical trial. In the second poster, we are pleased to share for the first time, work conducted in collaboration with Celldex Therapeutics showing that Exicure’s TLR9 agonist leads to improved anti-tumor response when combined with CDX-301,” said Dr. Giljohann.
The first poster, authored and presented by Exicure scientists, titled: "AST-008, a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and cytokines in healthy subjects in a Phase 1 clinical trial" demonstrates the utility of Exicure’s proprietary platform technology for targeting TLR9 to upregulate the immune system. Exicure’s drug, AST-008, is now enrolling patients in a Phase 1b/2 trial in patients with advanced solid tumors.
A second poster, to be presented by Celldex scientists, showcases data generated by Celldex Therapeutics, Inc. and Exicure through an ongoing scientific collaboration. The poster, titled: "Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA” highlights improved anti-tumor activity after administration of AST-008 in combination with CDX-301.
Details of the posters:
Title: AST-008, a TLR9 agonist spherical nucleic acid,
activated NK cells, T cells, and cytokines in healthy subjects in a
Phase 1 clinical trial.
Abstract/Poster No: CT044/1
Date of poster presentation: April 01, 2019, 8:00 AM - 12:00 PM ET
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17
Title: Preclinical evaluation of the recombinant dendritic
cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA
Abstract/Poster No: 3217/27
Date of poster presentation: April 02, 2019, 8:00 AM - 12:00 PM ET
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure's proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
Forward Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed Phase 1 trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.